Jim Cramer focuses on Blackberry, Exact Sciences, Splunk, Freeport-McMoRan and more.
Jim Cramer says it's more than just the cloud. There are some astounding moves in the broader tech sector, too.
AstraZeneca shares edged higher Tuesday as investors shrugged off a mixed set of phase-3 results for the Anglo Swedish drug maker's Bydureon Exscel type II diabetes treatment.
Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.